CHECKMATE-142-NIVO-MONO

NCT02060188 📎

Regimen

Experimental
Nivolumab 3 mg/kg Q2W
Control
single-arm

Population

dMMR/MSI-H metastatic CRC, 2L+, previously treated with fluoropyrimidine/oxaliplatin/irinotecan.

Key finding

ORR 31.1% (95% CI 20.8–42.9) in 74 pre-treated dMMR/MSI-H mCRC patients (≥1 prior line including fluoropyrimidine and oxaliplatin or irinotecan); disease control ≥12 weeks 69%; median duration of response not reached; 12-month OS 73%; grade 3–4 drug-related AEs: lipase increase 8%, amylase 3%; no treatment-related deaths.

Source: PMID 28734759

Timeline

    Guideline citations

    • NCCN Colon (p.59)
    • NCCN Rectal (p.76)